To date, the Corporation has:
Completed safety studies that include GLP toxicology and confirmed a favourable safety profile;
Completed preclinical immunogenicity studies showing potential for long-term protection with antibody titers
maintained throughout the duration of studies (day 140);
Completed a challenge study in ferrets that demonstrated reductions of viral load in the nasal tissue;
Demonstrated T-cell response and natural immunity in convalescent plasma against the targeted epitope peptides in
the DPX-COVID-19 formulation;
Qualified for approximately $10 million of non-dilutive funding from different Canadian governmental sources,
including up to $5.4 million in milestone-based payments;
Completed the current good manufacturing practice (cGMP) formulation and manufacturing process development for
clinical trials; and
Entered into a collaboration with a global manufacturing partner to transfer and scale-up activities of DPX-COVID-
19 in India and Europe with the anticipated capacity to produce several hundred million doses